RBC Capital Maintains Outperform on Lexeo Therapeutics, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has maintained an Outperform rating on Lexeo Therapeutics (NASDAQ:LXEO) and increased the price target from $22 to $24.
March 12, 2024 | 3:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has maintained an Outperform rating on Lexeo Therapeutics and raised the price target from $22 to $24.
The increase in price target by a reputable analyst firm like RBC Capital typically signals a strong confidence in the company's future performance, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100